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Abstract: Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human 
tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for 
immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated 
a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag 
to transform cells and to interact with anti-oncoproteins, as well as screened for the presence 
of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells 
with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is 
degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact 
with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes 
within mTag sequence were identiﬁ  ed. Our results show that mTag lacks the oncogenecity of 
full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence sug-
gesting the safety of vac-mTag for use in cancer immunotherapy.
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Introduction
Simian virus 40 (SV40) is a polyomavirus with DNA capable of transforming human 
and rodent cells in vitro and in vivo. SV40-transformed human cells are able to pro-
duce tumors when administered to nude mice (Brooks et al 1988; Reddel et al 1993). 
SV40 large T antigen (Tag), a multifunctional protein that orchestrates virtually every 
aspect of SV40 infection, is necessary and often sufﬁ  cient for tumorigenesis (Shah 
2000; Jasani et al 2001; Klein et al 2002; Garcea and Imperiale 2003).
At least a part of Tag’s ability to induce tumors stems from its ability to bind speciﬁ  c 
cellular tumor suppressor proteins, such as p53, pRb (retinoblastoma protein), and other 
Rb-related proteins (p107, p130, and p300), all of which exhibit properties of negative 
regulators of cell proliferation (Vilchez and Butel 2003a; Ahuja et al 2005).
Compelling evidence shows that SV40 homologous DNA sequences are present 
in human osteosarcomas, ependymomas, choroid plexus tumors, mesotheliomas, and 
non-Hodgkin’s lymphoma (Jasani et al 2001; Klein et al 2002; Garcea and Imperiale 
2003). This suggested a link between SV40 and carcinogenesis in humans. It has been 
strongly speculated that the failure to inactivate SV40 contamination in the poliovac-
cines and adenovaccines from 1955 to 1963 played a signiﬁ  cant role in introducing 
SV40 to humans (Butel and Lednicky 1999).
Although the direct role that SV40 Tag plays in tumorigenesis in humans is still to 
be determined, the fact that it is expressed in human tumor cells makes it a potential 
target for immunotherapy targeting these tumors.
Vaccinia virus recombinants are being used as efﬁ  cient tools for antigen delivery in 
cancer immunotherapy both in mice and humans (Shen and Nemunaitis 2005; Phelps 
et al 2007; Song et al 2007). We have constructed a vaccinia-based recombinant (vac-
mTag), safety-modiﬁ  ed version of SV40 Tag (mTag), devoid of pRb, p53 binding Drug Design, Development and Therapy 2008:2 18
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sites, and the amino-terminal oncogenic CR1 and J domains 
to optimize potential clinical safety, but still preserve immu-
nogenic domains. Our previous studies have shown that 
vac-mTag can induce tumor antigen-speciﬁ  c immunity in 
rodents (Xie et al 1999). In the present report, we describe the 
suitability of use of mTag in immunotherapy by evaluating 
both safety and immunogenicity of the protein.
Materials and methods
Plasmids
An approximately 2.2-Kb BamHI DNA fragment containing 
SV40 large Tag was cut out from pSP64-Tag (a kind gift from 
Dr J Butel, Baylor College of Medicine, Houston, TX), sub-
cloned onto pcDNA3 (Invitrogene, Carlsbad, CA) at BamHI 
site, and named Tag/pcDNA3. The orientation of Tag was 
veriﬁ  ed by PstI and XhoI digestions. pSC65-mTag plasmids 
(Xie et al 1999) were digested with BglII and PacI to recover 
an about 1.1-Kb DNA fragment containing mTag and the 
mTag DNA fragments were then ligated to pcDNA3 plasmids 
digested with BamHI and EcoRV. The resulting product was 
a 6.5-Kb linear DNA fragment carrying ligated pcDNA3 and 
mTag through the BamHI and BglII site, respectively. The 
linear DNA fragment was then run on a 0.8% agarose gel, 
recovered, and blunt-ended at the PacI end with Mung Bean 
Nuclease (Life Technologies, Inc., Gaithersburg, MD). The 
blunt-ended products were subjected to a ligation reaction to 
form a circular plasmid through the EcoRV of pcDNA3 and 
the blunt-ended PacI of mTag and named mTag-pcDNA3. 
Two independent clones were used for the experiments.
Cell lines
BALB/c 3T3 embryonic ﬁ  broblast cell line was obtained 
from ATCC (Manassas, VA). 209 R1B1, an SV40-infected 
cell line, has been described previously (Bender et al 1983). 
All cell lines in this study were maintained in complete 
Dulbecco’s Modiﬁ  ed Eagle’s Medium (DMEM). Geneticin 
was used to select plasmid-carrying cells.
Transfection and transformation assays
105 BALB/c 3T3 cells/well were transfected with 5 μg of 
empty pcDNA3, TagpcDNA3, and/or mTagpcDNA3 using 
the transfection kit ProFection (Promega, Madison, WI). Cells 
were then washed once and incubated in fresh medium for 
24 hours. Approximately 6/10 of the cells from each well were 
transferred onto a 100 mm culture dish for examining focus-
formation on monolayer cells. 3/10 of the cells were grown in 
media supplemented with a ﬁ  nal concentration of 500 μg/ml 
of Geneticin to select for transfectants for soft agar assays. The 
remaining 1/10 cells were subjected to Geneticin selection to 
determine transfection efﬁ  ciency for each plasmid.
For the focus-formation on monolayer cells, 100 mm cul-
ture dishes were incubated at 37 °C/5% CO2 for four weeks. 
Cells were then stained with 0.5% Wright’s dye. Cells were 
washed and air-dried before the pictures were taken.
To set up soft agar assays, 10,000 transfectants in 1 ml 
of medium were mixed with 1 ml of medium containing 
2% agarose LE. The mixture was plated on top of solidiﬁ  ed 
bottom agar (7 ml of 2% agarose LE-containing medium) 
on 60 mm culture dishes and incubated at 37 °C/5% CO2 for 
6 weeks. A small amount (~0.5 ml) of fresh liquid media was 
added onto the plates occasionally during the incubation to 
prevent solid media from drying out. Colony numbers were 
then scored under a microscope.
Immunoprecipitation
Cells were collected after incubation in media containing 1 mM 
EGTA for about 16 hours and resuspended in 0.5 ml iced-cold 
cell lysis buffer (50 mM Tris-HCl [pH. 7.5], 120 mM NaCl, 
5 mM EDTA, 0.05% IGEPAL CA-630, 1 μg/ml Aprotinin, 
1 μg/ml Leupeptins, and 1 μg/ml Pepstatin A) and incubated 
on ice for 10 minutes. Cells in suspension were lysed in a glass 
dounce homogenizer (Knotes) on ice. The crude cell lysates 
were cleared by centrifugation and protein concentration 
was determined by the Bradford assay. Immunoprecipita-
tion assays were performed using the Seize X Protein G kit 
(Pierce, Rockford, IL) following the manufacturer’s protocol. 
Immunoprecipitated proteins on each column were eluted 
with 190 μl of elution buffer after extensive washing. The 
eluted protein products were neutralized with 10 μl of 1 M 
Tris-HCl, pH. 9.5 and separated by SDS-PAGE.
Western immunoblot
Proteins were separated on SDS-PAGE and transfered to 
a Hybound-P membrane (Amersham Pharmacia Biotech, 
Piscataway, NJ). The membrane was blocked with 5% non-
fat dry milk in TBS-T. Antibodies against Pab204, pRb and 
p53 were added at appropriate dilutions in 2% nonfat milk/1X 
TBS-T and incubated at room temperature for 2 hours. The 
membrane was then washed and incubated with a suitable 
secondary antibody, and then washed, developed using the 
ECL+Plus chemiluminescence detection system (Amersham 
Pharmacia Biotech), and exposed to X-ray ﬁ  lms.
T2-loading assay
Potential HLA-A2.1-restricted peptides were predicted 
using the algorithm BIMAS (see http://bimas.dcrt.nih.gov/Drug Design, Development and Therapy 2008:2 19
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cgi-bin/molbio/ken_parker_comboform). For the MHC class 
I stabilization assay, 2 × 105 T2 cells (ATCC; Manassas, VA) 
in 1 ml of serum-free medium were incubated overnight at 
37 °C/5% CO2 with 50 μg/ml of testing [Tag 8 (WLHCLLPKM) 
and Tag 27 (VAIDQFLVV)] and control peptides [Tag 37 
(KCDDVLLLL) (16) and Tag II/III (CKGVNKEYL)]. Cells 
were then washed and labeled with anti-HLA-A2.1 antibody 
(One Lambda Inc.; Canoga Park, CA) and the intensity of 
HLA-A2.1 expression determined by ﬂ  ow cytometry.
ELISPOT
HLA-A*0201/Kb-transgenic mice (generated by Dr Linda 
Sherman at The Scripps Research Institute, La Jolla, CA) 
were purchased from Harlan Sprague-Dawley (Indianapolis, 
IN) were immunized with 107 pfu of vac-mTag through tail-
vein injection. Three weeks later, spleens were harvested and 
CD8+ T cells were isolated from splenocytes using negative 
selection kits from Miltenyi Biotec Inc. (Auburn, CA) follow-
ing the manufacturer’s protocol. DCs were derived from bone 
marrow using IL-4 and GM-CSF as described previously 
with some modiﬁ  cations (Inaba et al 1992). DCs were loaded 
overnight with individual peptides (20 mg/ml). The next day, 
peptide-loaded DCs were irradiated with 5,000 rads.
For the ELISPOT assay, multiscreen 96-well plates were 
coated with capture anti-IFNγ Ab (4 μg/ml; PharMingen; San 
Diego, CA) overnight at 4 °C, washed and blocked with 1% 
BSA/1X PBS (150 μl/well). One million CD8+ splenocytes 
and 0.1 million of peptide-loaded DCs were seeded into 
each well and the plates were incubated at 37 °C/5% CO2 for 
24 hours. The plates were washed and 100 μl/well of bioti-
nylated rat anti-mouse IFNγ Ab (2 μg/ml; PharMingen) were 
added and incubated overnight at 4 °C. On day 3, the plates 
were washed and 100 μl/well of anti-biotin Ab (1:1000 dilu-
tion; Vector; Burtingame, CA) were added and left for 90 min. 
The plates were washed and developed with NBT/BCIP. The 
number of spots was determined using an ELISPOT reader 
(Cell Technology Laboratory, Inc.; Cleveland, OH).
Statistical analysis
Statistical analysis was performed where appropriate using 
Student’s T-test. Differences were considered as signiﬁ  cant 
when the p value was 0.05.
Results
mTag-bearing plasmids do not induce 
transformation in BALB/c 3T3 cells
We ﬁ  rst assessed the ability of Tag- and mTag-bearing 
plasmids to transform transfected cells. To this aim, we used 
focus-formation on monolayer cells and colony formation 
on soft agar. BALB/c 3T3 cells were transfected with empty 
vectors, Tag-pcDNA3, and/or two independent clones of 
mTag-pcDNA3. Transfected cells were plated onto 100 mm 
culture dishes separately without geneticin selection to look 
for focus-formation. 209R1B1 cells, which are BALB/c 
3T3 cells with integrated SV40 DNA and carry at least two 
copies of Tag (Bender et al 1983), were plated as a positive 
control. As expected, numerous foci were found on plates 
with 209R1B1 cells after four weeks of incubation. Approxi-
mately a hundred foci were observed on each plate with cells 
transfected with Tag-pcDNA3 as well. In contrast, only a 
few foci developed on the plates with cells transfected with 
empty vectors or mTag-pcDNA3 (Figure 1).
For soft agar assays, cells were subjected to geneticin 
treatment to select for transfectants. 10,000 transfectants 
were then plated onto each soft agar plate. Colonies grow-
ing on each plate were counted after six weeks of incuba-
tion. Approximately 20% of 209R1B1 cells and 2% of cells 
transfected with Tag-pcDNA3 were able to form colonies 
on soft agar, whereas less than 0.1% cells transfected with 
empty plasmids and/or the two independent clones of mTag-
pcDNA3 exhibited growth (Figure 1).
mTag protein is expressed in transfected 
cells and subjected to a faster proteolytic 
degradation in vivo compared with SV40 Tag
We further sought to evaluate the expression of mTag 
protein in transfected cells. Cell extracts were prepared 
and subjected to Western blot analysis using Pab204, a 
monoclonal anti-Tag antibody which has been shown to 
be able to detect both full-length Tag and mTag proteins 
(Xie et al 1999). The 42-kDa band corresponding to mTag 
protein was not detectable by Western blot in cell extracts 
of cells transfected with two independent clones of mTag-
pcDNA3 after long exposures (Figure 2). In contrast, 
RT-PCR and Northern blot analysis showed that there was 
at least equal amount of steady-state mTag mRNA com-
pared to that of full-length Tag in cells (data not shown). 
These observations indicated that mTag was expressed and 
suggested that mTag protein might be unstable in cells. 
To investigate this possibility, cells were pre-treated with 
EGTA prior to cell lysate preparation to decrease protease 
activity. Interestingly, a robust expression of mTag proteins 
could be detected after the EGTA treatment (Figure 2). 
This result indicates that mTag protein was synthesized in 
mTag-pcDNA3-transfected cells and is highly sensitive to 
protease degradation.Drug Design, Development and Therapy 2008:2 20
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Figure 1 Focus-formation on monolayer cells. (A) BALB/c 3T3 cells transfected with pcDNA3, Tag-pcDNA3, mTag-pcDNA3 clone 1 (mTag-pcDNA3-1), and mTag-
pcDNA3 clone 2 (mTag-pcDNA3-2), and 209 R1B1 cells (BALB/c 3T3 cells infected with SV40) were plated. Four weeks later, cells were stained with 0.5% Wright’s stain in 
methanol. Each dish is a representative of four plates in two independent transformation assays. (B) Numbers of colonies growing on soft agar (50 cells). Statistical analy-
sis showed that colony formation after transfection with Tag-pcDNA3 was greater (p = 0.001, T-test) than transfection with pcDNA3 vector (negative control). In contrast, 
mTag-pcDNA3 transfection did not show signiﬁ  cant increase of colony numbers over pcDNA3 background.
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Figure 2 Expression and stability of Tag and mTag proteins in transfected 3T3 cells. Protein extracts were prepared from transfected cells with or without 1 mM EGTA 
treatment. 100 μg of total proteins from each extract were separated by a 10% SDS-PAGE and transferred to nitrocellulose membrane. The membrane was probed with 
Pab204 (a monoclonal anti-Tag (mTag) antibody), HRP-conjugated goat anti-mouse antibody, and developed with ECL-Plus reagent. Protein extracts of 209 R1B1 and BALB/c 
3T3 cells were used as positive and negative control for SV40 Tag protein. vac-mTag-infected CV-1 cells (vac-mTag/CV-1) served as a positive control for mTag protein.
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mTag proteins do not physically interact 
with pRb and/or p53
Because SV40 Tag exerts its oncogenecity mainly through its 
interaction with regulators of cell growth, such as as pRb and 
p53, we designed a safety-modiﬁ  ed version (mTag) that lacks 
the pRb- and p53-interacting domains, as well as the amino-
terminal oncogenic CR1 and J domains (Xie et al 1999). To 
prove the loss of interaction of mTag with pRb and p53, cell 
extracts were prepared after EGTA treatment and subjected 
to immunoprecipitation using anti-pRb (Figure 3A) and/or 
anti-p53 antibodies (Figure 3B). To include approximately 
equal amounts of p53 protein in the immunoprecipitation 
assays using anti-p53 antibodies, ﬁ  ve times lesser amount 
of total proteins of Tag-expressing lysates (Tag-pcDNA3 
and COS-1) were used in the reactions (Figure 3B, top 
panel). As expected, both anti-pRb and anti-p53 antibod-
ies co-precipitated full-length Tag (Figure 3A and B), but 
not mTag (Figure 3C). Immunoprecipitation assays were 
subsequently performed using Pab204 as well. Consistent 
with above results, immunoprecipitated-Tag protein, but 
not mTag protein, pulled down both pRb and p53. Taken 
together, these data suggest that mTag, in contrast to Tag, 
does not physically interact with pRb and/or p53.
Identiﬁ  cation of two novel potential 
HLA-A2.1-restricted epitopes within 
mTag sequence
Having established the safety of mTag, we further evalu-
ated its immunogenic potential by screening its sequence 
for potential HLA-A2.1-restricted epitopes. We tested two 
peptides (Tag 8 and Tag 27) in addition to a previously iden-
tiﬁ  ed A2.1-restricted epitope (Tag 37) (Schell et al 2001), 
which also localizes within mTag sequence. Both peptides 
(Figure 4A; Tag 8: lower left; Tag 27: lower right) as well 
as Tag 37 (upper right), but not a negative control peptide 
(Tag II/III; H2-Db) (light grey) (Tanaka et al 1988), exhibited 
binding to HLA-A2.1 molecules on T2 cells, as compared 
with unloaded T2 cells (upper left; dark grey).
To determine if the binding peptides could be functional 
HLA2-A2.1 epitopes, we used the IFN-γ ELISPOT assay 
to examine whether elicited CD8+ splenocytes from vac-
mTag immunized HLA-A2.1 transgenic mice were capable 
of responding to peptide-specific stimulation. Peptides 
were loaded onto A2.1 Dendritic Cells (DCs) to serve as 
stimulators for the ELISPOT assay. vac-mTag immunization 
elicited CD8+ splenocytes that responded to Tag 23 stimula-
tion, compared to that of unloaded DCs. This response was 
Figure 3 mTag protein does not physically interact with pRb or p53. Protein 
extracts were prepared from 1 mM EGTA-treated transfected- and virus infected-
cells. Immunoprecipitation assays were performed using monoclonal anti-human 
pRb antibody at 1:50 dilution (A), monoclonal anti-human p53 antibody at 1:50 
dilution (B), and/or Pab204 at 1:250 dilution (C) in a ﬁ  nal volume of 0.5 ml. 1 mg 
total proteins were used in each immunoprecipitation reaction, except for SV40 
Tag-containing lysates (Tag/pcDNA3 and COS-1; 200 μg total proteins were used 
per reaction) in (B) to include approximately same amount of p53. The eluted 
immunoprecipitation products were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. Western blots were performed with monoclonal anti-
human pRb at 1: 330 dilution, rabbit polyclonal anti-p53 antiserum at 1: 250 dilution, 
and Pab204 at 1: 5000 dilution to detect the proteins of interest. LnCap and 
DU145 cells lysates were used as a positive and a negative control for pRb. J82 cells 
transfected with p53-carrying plamids (p53/J82) and J82 extracts were a positive 
and a negative control for p53. Lysates of 209 R1B1 and BALB/c 3T3 cells served as 
a positive and a negative control for SV40 Tag protein. CV-1 infected with vac-mTag 
(vac-mTag/CV-1) was a positive control for mTag protein.
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mTag-speciﬁ  c as the CD8+ splenocytes from A2.1 mice 
immunized with a control vaccinia (vac-PSA) did not respond 
to Tag 23 stimulation. Compared to Tag 23, Tag 8 and 37 
peptides induced signiﬁ  cantly lower reactions (Figure 4B).
Discussion
We have previously characterized vac-mTag, a recombi-
nant vaccinia virus expressing a safety-modiﬁ  ed version 
of SV40 Tag, that confers protection against tumors and 
provides therapeutic efﬁ  cacy against pre-established SV40 
Tag-expressing tumors in rodents (Xie et al 1999). Since 
SV40 Tag protein is a potent oncoprotein, it is therefore 
crucial to address the safety of mTag as a therapeutic.
It is well established that expression of SV40 Tag 
in rodent cells, such as BALB/c 3T3 cells, leads to cell 
transformation, including focus-formation on monolayer 
cells and ability to grow on soft agar. These characteristics 
of transformed cells were therefore adopted to examine if 
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Figure 4 mTag harbors two HLA-A2.1-restricted functional epitopes. (A) 50 μg/ml of Tag 8 (c; empty) and Tag 27 (d; empty) peptides as well as a known peptide (Tag 37; b; 
empty) and a negative control peptide (a–d; light grey) were loaded onto T2 cells in serum-free medium overnight at 37 °C. Unloaded T2 cells served as a control (a; dark 
grey). Cells were then stained with a FITC-conjugated anti-HLA-A2.1 antibody, and analyzed by ﬂ  ow cytometry. (B) Mouse IFN-γ ELISPOT showed elicited responses fol-
lowing the restimulation of vac-mTag-elicited CTL with each epitope candidate. Data shown represent the Mean ± SEM from 3 experiments.
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mTag protein retains the oncogenic ability of its full-length 
version. As expected, SV40 Tag-transfected cells formed 
hundreds of foci on monolayer cells and acquired the abil-
ity to grow on soft agar. In contrast, mTag-tranfected cells 
neither formed foci on monolayer cells nor grew on soft agar 
when expressed in BALB/c 3T3 cells. This indicates that 
mTag-transfected cells were not transformed. The expres-
sion of mTag was demonstrated by RT-PCR and Northern 
analyses (data not shown). Additionally, the transfection 
efﬁ  ciency of Tag- and/or mTag-carrying plasmids was nearly 
identical (10%–15%; data not shown).
To test the stability of mTag in transfected cells, mTag-
transfected cells were treated with EGTA to decrease cel-
lular protease activity before cell lysate preparation. Under 
these conditions, the presence of mTag protein was readily 
detected, suggesting that mTag protein was indeed unstable. 
The labile nature of mTag protein could be attributed to the 
fact that it is a truncated form of protein and is hence unable 
to fold into a correct and stable structure. In addition, mTag 
protein lacks the Nuclear Localization Signal (NLS) of 
full-length Tag and is localized into the cytoplasm (data not 
shown), which is not a native environment for SV40 Tag 
protein. Accordingly, the mis-localization of mTag protein 
may also contribute to its unstable behavior. The short life 
span of mTag protein, which further reduces its capability 
to interact with anti-oncoproteins, provides an additional 
safety feature for mTag. The fact that mTag protein does not 
transform rodent cells, a preferred system for the oncogeneity 
of SV40 Tag compared to human cells, suggests that mTag 
protein is unlikely to be able to transform mammalian cells 
in general.
mTag was constructed to exclude the oncogenic motifs 
of full-length Tag, mostly the domains interacting with 
anti-oncoproteins. To conﬁ  rm the loss of oncogenicity, 
immunoprecipitation assays using an anti-pRb, an anti-p53 
antibody, and/or an anti-Tag (mTag) antibody (Pab204) 
were employed. In contrast to the full-length Tag protein, 
mTag protein neither co-immunoprecipitated with pRb nor 
with p53 under a condition where mTag protein was stable 
due to EGTA treatment. Previous studies have shown that 
the expression of Tag protein leads to an over-expression 
of p53 (Deppert et al 1987; Kohli and Jorgensen 1999). 
Western blot using a monoclonal anti-p53 antibody indeed 
revealed that there was a robust expression of p53 in cells 
transfected with Tag-pcDNA3, but not in cells transfected 
with either clone of mTag-pcDNA3 clone (data not shown). 
Immunoprecipitation assays using an anti-p53 antibody 
was designed in such a way to include approximately equal 
amounts of p53. Consequently, the failure of anti-53 antibody 
to co-immunoprecipitate mTag protein was not due to the fact 
that there was less p53 protein in the starting lysates. Addi-
tionally, it is thought that the reason for an over-expression 
of p53 in SV40 Tag-expressing cells is caused, in part, by the 
binding of Tag to p53 that leads to its stabilization (Deppert 
et al 1987). These results were further supported by the fact 
that p53 levels were not elevated in cells transfected with 
mTag-pcDNA3, showing that there is no physical interac-
tion between mTag protein and p53. Interestingly, we also 
observed an over-expression of pRb in CV-1 cells infected 
with vaccinia virus (Figure 3A, top panel). When cell 
lysates prepared from CV-1 cells infected with vac-mTag 
were used in immunoprecipitation assays, anti-pRb failed to 
co-immunoprecipitate mTag. These data showed that mTag 
does not interact with pRb even in a condition when pRb 
is unusually abundant. Therefore, our results conclusively 
demonstrated that mTag, unlike full-length Tag, does not 
interact with pRb and/or p53.
Schell and colleagues (2001) have previously identiﬁ  ed 
a human HLA-A2.1-restricted epitope (Tag 37) from Tag. 
Here we identiﬁ  ed two new potential epitopes within mTag 
sequence capable of binding to HLA-A2.1 molecules. It is 
worthy of noting that both our peptides caused greater sta-
bilization of HLA-A2.1 compared with Tag 37, as judged 
by the shift in HLA-A2.1 expression intensity on T2 cells 
following peptide loading (MFI units 19.1, 25.7 and 18.8 
for Tag 8, Tag 27 and Tag 37, respectively), suggesting 
that Tag 8 and Tag 27 are stronger binders to HLA-A2.1. 
Consistent with the binding proﬁ  le of these peptides, Tag 
23 elicited stronger CTL activity than did Tag 8 or Tag 
37. Although Tag 23 was able to induce detectable CTL 
activity, the number of Tag 23-speciﬁ  c population was 
relatively low (10–80 per millioin CD8+ splenocytes) com-
pared with the well-studied H2-Kb-restricted Tag epitope 
(epitope IV (Mylin et al 1995); 1200–1500 per million CD8+ 
splenocytes; data not shown) in a similar setting. The low 
expression of HLA-A2.1 in A2.1 mice may account for 
the relatively low reaction we observed in this study. Also, 
in the present work, we did not test the ability of the CTL 
elicited by these mTag-derived peptides to recognize tumor 
cells expressing full length Tag. This is due to the fact that 
we have previously demonstrated that immunization of 
mice with mTag included an SV40 Tag-speciﬁ  c cytolytic 
T-lymphocyte activity against syngeneic (identical genetic 
background) SV40 Tag-expressing tumor targets, and 
immunization of mice with a single dose of mTag-expressing 
vaccinia (vac-mTag) resulted in potent protection against Drug Design, Development and Therapy 2008:2 24
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subsequent challenge with a lethal mouse cancer expressing 
SV40 Tag (Xie et al 1999).
Research utilizing HLA-A2.1 transgenic mice lacking the 
mouse MHC I (HHD mice) will be able to provide us with 
more insight into the strength of the epitopes. Additionally, 
the algorithm we used to predict binding epitopes has gener-
ated many other potential HLA2-A2.1 epitopes within mTag 
sequence, which could be evaluated in future studies.
Although involvement of SV40 Tag in neoplastic cell 
transformation in humans remains controversial, its presence 
in a variety of human tumors is well established (Carbone 
et al 1997; Butel and Lednicky 1999; Shah 2000; Jasani et al 
2001; Klein et al 2002; Garcea and Imperiale 2003; Vilchez 
and Butel 2003b). SV40 Tag protein is therefore a potential 
target for immunotherapy. In our previous (Xie et al 1999) 
and present report, we have shown that mTag protein is 
immunogenic but deprived of its oncogenic potential. Our 
work provides an initial safety characterization of mTag 
protein and a rationale for using vac-mTag as a tool in 
immunotherapy in humans.
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